Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024. As announced on 14 February 2023, the Company initiated…
Cyprium Metals Limited (ASX: CYM) (Cyprium or the Company) is pleased to advise that it has entered into a…
Eric Sprott announces that today, 2176423 Ontario Ltd., a corporation which is beneficially owned by him, purchased 770,000 common…
Overview The global regulatory climate around cannabis use is evolving and has resulted in a huge investment opportunity for…
Nova Minerals Limited (Nova or the Company) (ASX: NVA, NASDAQ: NVA, NVAWW OTC: NVAAF, FSE: QM3) is pleased to…
Strategic Resources Inc. (TSXV: SR) (the ‘Company’ or ‘Strategic’) is pleased to announce that it has engaged Societe Generale…
After reaching a 17 year high in January, uranium prices consolidated in Q2, holding above US$82 per pound. Despite…
Google (NASDAQ:GOOGL) parent company Alphabet reported its second quarter results headlined by US$84.74 billion in revenue, showcasing solid growth…
Description The securities of Adisyn Ltd (‘AI1’) will be placed in trading halt at the request of AI1, pending…